PDSB PDS Biotechnology Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: PDSB

Price (delayed)

$3.82

Market cap

$140.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.39

Enterprise value

$107.41M

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively ...

Highlights
PDS Biotechnology's EPS has increased by 19% QoQ and by 2.8% YoY
The equity has contracted by 41% YoY but it has grown by 7% from the previous quarter
PDS Biotechnology's net income has increased by 16% from the previous quarter but it has decreased by 5% YoY
The quick ratio is down by 45% YoY and by 30% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.pdsbiotech.com
Peers: OMER OMGA

Key stats

What are the main financial stats of PDSB
Market
Shares outstanding
36.68M
Market cap
$140.11M
Enterprise value
$107.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.55
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$43.05M
EBITDA
-$42.87M
Free cash flow
-$33.64M
Per share
EPS
-$1.39
Free cash flow per share
-$1.09
Book value per share
$0.84
Revenue per share
$0
TBVPS
$1.92
Balance sheet
Total assets
$59.39M
Total liabilities
$33.26M
Debt
$23.85M
Equity
$26.13M
Working capital
$45.43M
Liquidity
Debt to equity
0.91
Current ratio
4.33
Quick ratio
4.15
Net debt/EBITDA
0.76
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-69%
Return on equity
-138.4%
Return on invested capital
-239.8%
Return on capital employed
-94.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PDSB stock price

How has the PDS Biotechnology stock price performed over time
Intraday
2.41%
1 week
16.82%
1 month
3.8%
1 year
-39.17%
YTD
-23.14%
QTD
-3.54%

Financial performance

How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$43.05M
Net income
-$42.94M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 16% from the previous quarter but it has contracted by 3.3% YoY
PDS Biotechnology's net income has increased by 16% from the previous quarter but it has decreased by 5% YoY

Growth

What is PDS Biotechnology's growth rate over time

Valuation

What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
4.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has increased by 19% QoQ and by 2.8% YoY
The equity has contracted by 41% YoY but it has grown by 7% from the previous quarter
The P/B is 34% higher than the 5-year quarterly average of 3.4 but 16% lower than the last 4 quarters average of 5.4

Efficiency

How efficient is PDS Biotechnology business performance
PDSB's ROE has shrunk by 68% YoY but it is up by 4% QoQ
PDS Biotechnology's ROIC has increased by 50% YoY and by 12% from the previous quarter
The ROA is down by 13% YoY but it is up by 10% QoQ

Dividends

What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PDSB.

Financial health

How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 79% more than its total liabilities
The quick ratio is down by 45% YoY and by 30% from the previous quarter
PDSB's current ratio is down by 44% year-on-year and by 30% since the previous quarter
PDS Biotechnology's debt is 9% lower than its equity
The debt to equity has soared by 72% year-on-year but it has declined by 5% since the previous quarter
The equity has contracted by 41% YoY but it has grown by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.